ReviewThe Eurasian journal of medicine2019
Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.
Review in The Eurasian journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Neuropeptides and endocannabinoid system as regulators of blood pressure in adolescents with primary hypertension.Medicine · 2026Article
- Nesfatin-1 as a Potential Biomarker for Ischemic Stroke: A Case-Controlled Study of a Comparative Analysis of Patients with and Without Internal Carotid Artery Stenosis.Diagnostics (Basel, Switzerland) · 2025Article
- The tissue distribution of nucleobindin-2/nesfatin-1 in the reproductive organs of bitches with regard to the animal's age and body weight.Journal of veterinary research · 2025Article
- Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1.BMC endocrine disorders · 2024Article
- Article
- Dynamics of Serum Inflammatory Markers and Adipokines in Patients: Implications for Monitoring Abnormal Body Weight: Preliminary Research.Metabolites · 2024Article
- Article
- Interaction between Selected Adipokines and Musculoskeletal and Cardiovascular Systems: A Review of Current Knowledge.International journal of molecular sciences · 2023Review
- The Role of Adipokines and Myokines in the Pathogenesis of Different Obesity Phenotypes-New Perspectives.Antioxidants (Basel, Switzerland) · 2023Review
- Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.Journal of cardiovascular development and disease · 2023Review
- State of art on the mechanisms of laparoscopic sleeve gastrectomy in treating type 2 diabetes mellitus.World journal of diabetes · 2023Review
- Intraperitoneal administration of nesfatin‑1 stimulates glucagon‑like peptide‑1 secretion in fasted mice.Molecular medicine reports · 2023Article
- Protective role and molecular mechanism of action of Nesfatin-1 against high glucose-induced inflammation, oxidative stress and apoptosis in retinal epithelial cells.Experimental and therapeutic medicine · 2021Article
- Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model.Molecular biology reports · 2021Article
- Nesfatin-1 Promotes the Osteogenic Differentiation of Tendon-Derived Stem Cells and the Pathogenesis of Heterotopic Ossification in Rat Tendons via the mTOR Pathway.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome is associated with a group of conditions abdominal obesity, high triglyceride levels, reduction in low-density lipoprotein, increased blood pressure, and increased fasting blood glucose. Hence, it poses a risk for type 2 diabetes and cardiovascular diseases. The prevalence of metabolic syndrome increases with age. Nesfatin-1, which affects different systems, has recently been discovered as a regulatory peptide molecule. With the discovery of nesfatin-1, it has been reported to inhibit the intake of nutrients and have significant regulatory effects on energy metabolism. As nesfatin-1 is present in both central and peripheral tissues, it is thought to have many functions. In addition to its suppressive effect on food intake, nesfatin-1 has also been reported to have an effect on the blood glucose level for regulating cardiac functions and affecting obesity by providing weight loss. Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.